Document is current
Any future updates will be listed below
-
Authors
Sheridan Rains, Luke https://orcid.org/0000-0003-4905-4168
Marston, Louise
Hinton, Mark
Marwaha, Steven
Craig, Thomas
Fowler, David
King, Michael
Omar, Rumana Z.
McCrone, Paul
Spencer, Jonathan
Taylor, Joanne
Colman, Sophie
Harder, Catherine
Gilbert, Eleanor
Randhawa, Amie
Labuschagne, Kirsty
Jones, Charlotte
Stefanidou, Theodora
Christoforou, Marina
Craig, Meghan
Strang, John
Weaver, Tim
Johnson, Sonia
-
Funding
Funding for this research was provided by:
Health Technology Assessment Programme (09/144/50)
- License Information
-
More Information
Article History
Received: 23 January 2019
Accepted: 22 July 2019
First Online: 15 August 2019
Ethics approval and consent to participate
: Ethical approval for the trial was received on 16 March 2012 from the London – South East National Research Ethics Service committee (REC reference 11/LO/1939). All participants provided written informed consent.
: Not applicable.
: This trial was funded by the National Institute for Health Research, Health Technology Assessment programme (09/144/50), and MK is a member of CTUs funded by NIHR and the Rapid Trials and Add-on Studies Board. RM is a member of the HTA General Board. JS is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. JS reports grants from Camurus (Lund, Sweden), Martindale Pharma (now Ethypharm UK, Woodburn Green, UK), Mundipharma (Mundipharma International Limited, Cambridge, UK) and Braeburn Pharma (Braeburn Inc., Plymouth Meeting, PA, USA), and other from Martindale Pharma, Braeburn Pharma outside the submitted work. In addition, John Strang has patents unrelated to the work described in this article: a patent Euro-Celtique issued and a patent King’s College London pending.
